SAMJIN PHARMACEUTICAL CO.,LTD
Financials
Valuation Metrics
SAMJIN PHARMACEUTICAL CO.,LTD's Market Cap is ₩2459B. At end of 2025 it was ₩2631B. Ranked #747 of 2,421 in KR market (top 31%), #417 of 781 on KOSPI (top 53%), #81 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 35%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 245.89B KRW | KR#747/2,421 Sec#81/231 |
| Revenue | 311.37B KRW | KR#813/2,421 Sec#37/231 |
| Net Income | 23.26B KRW | KR#648/2,421 Sec#41/231 |
| Total Assets | 476.87B KRW | KR#792/2,421 Sec#47/231 |
| Net Assets | 298.77B KRW | KR#721/2,421 Sec#48/231 |
| Employees | 809 | KR#311/2,421 Sec#27/231 |
| Value | ||
| P/E | 10.57x | KR#844/2,421 Sec#43/231 |
| P/B | 0.82x | KR#1,290/2,421 Sec#82/231 |
| PEG | 0.59x | KR#710/2,421 Sec#45/231 |
| P/S | 0.79x | KR#1,231/2,421 Sec#67/231 |
| EV/EBITDA | 14.64x | KR#840/2,421 Sec#51/231 |
| FCF Yield | 9.14% | KR#637/2,421 Sec#30/231 |
| Profitability | ||
| ROE | 7.79% | KR#810/2,421 Sec#54/231 |
| ROA | 4.88% | KR#758/2,421 Sec#60/231 |
| Op. Margin | 7.94% | KR#664/2,421 Sec#54/231 |
| Revenue Growth | 0.28% | KR#1,515/2,421 Sec#151/231 |
| Earnings Growth | 17.82% | KR#708/2,421 Sec#47/231 |
| Financial Health | ||
| Debt Ratio | 59.61% | KR#1,087/2,421 Sec#127/231 |
| Total Debt | 129.00B KRW | KR#648/2,421 Sec#37/231 |
| FCF | 22.47B KRW | KR#486/2,421 Sec#28/231 |
| Cash | 12.80B KRW | KR#1,548/2,421 Sec#127/231 |
| Current Ratio | 1.32x | KR#1,361/2,421 Sec#144/231 |
| Net Debt/EBITDA | 4.70x | KR#1,009/2,421 Sec#75/231 |
| Dividend | ||
| Div. Yield | 4.33% | KR#371/2,421 Sec#12/231 |
| Div. Growth | 0.00% | KR—/2,421 Sec—/231 |
| Performance | ||
| 1Y Return | -5.14% | KR#840/2,421 Sec#52/231 |
| 1M Return | 5.49% | KR#717/2,421 Sec#50/231 |
| From 52W High | -28.73% | KR#494/2,421 Sec#29/231 |
| 1Y MDD | -31.13% | KR#284/2,421 Sec#18/231 |
| Trading | ||
| Volume | 22,897 shares | KR#1,517/2,421 Sec#149/231 |
| Trading Value | 422.5M KRW | KR#993/2,421 Sec#99/231 |
| Foreign Own. | 3.68% | KR#1,122/2,421 Sec#104/231 |
| Per Share | ||
| EPS | 1,746 KRW | KR#490/2,421 Sec#31/231 |
| BPS | 22,430 KRW | KR#496/2,421 Sec#34/231 |
Company Info
Samjin Pharmaceutical, established in 1968, manufactures and sells pharmaceuticals, boasting a diverse portfolio that includes Gabol tablets and Plaless tablets. The company is expanding its business into health functional foods, cosmetics, and medical devices, with a strong focus on developing new drugs for conditions such as cancer and dementia. Following the completion of an EU-GMP-grade injectable line at its Osong raw material synthesis plant in 2022, Samjin Pharmaceutical is boosting production and facility investments for global growth. Samjin Pharmaceutical is headquartered in Mapo-gu, Seoul.